Market Research Logo

Gastroenteritis - Pipeline Review, H2 2015

Gastroenteritis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Gastroenteritis - Pipeline Review, H2 2015’, provides an overview of the Gastroenteritis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroenteritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroenteritis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gastroenteritis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gastroenteritis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gastroenteritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gastroenteritis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gastroenteritis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gastroenteritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Gastroenteritis Overview
Therapeutics Development
Pipeline Products for Gastroenteritis - Overview
Pipeline Products for Gastroenteritis - Comparative Analysis
Gastroenteritis - Therapeutics under Development by Companies
Gastroenteritis - Therapeutics under Investigation by Universities/Institutes
Gastroenteritis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Gastroenteritis - Products under Development by Companies
Gastroenteritis - Products under Investigation by Universities/Institutes
Gastroenteritis - Companies Involved in Therapeutics Development
Cocrystal Pharma, Inc.
Nanotherapeutics, Inc.
RedHill Biopharma Ltd.
Takeda Pharmaceutical Company Limited
UMN Pharma Inc.
Gastroenteritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antibodies for Gastroenteritis - Drug Profile Product Description
Mechanism of Action
R&D Progress
Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
norovirus (bivalent) virus like particle vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ondansetron hydrochloride CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Acute Gastroenteritis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-214 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UMN-2002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UMN-2003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gastroenteritis - Recent Pipeline Updates
Gastroenteritis - Product Development Milestones
Featured News & Press Releases
Oct 14, 2015: RedHill Biopharma Provides Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D
Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting
Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis
Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support
Sep 03, 2014: RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis
Dec 08, 2011: The New England Journal Of Medicine Publishes Study Showing LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness
Oct 25, 2010: LigoCyte Presents Positive Results From Norovirus Vaccine Challenge Study At IDSA Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Gastroenteritis, H2 2015
Number of Products under Development for Gastroenteritis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Gastroenteritis - Pipeline by Cocrystal Pharma, Inc., H2 2015
Gastroenteritis - Pipeline by Nanotherapeutics, Inc., H2 2015
Gastroenteritis - Pipeline by RedHill Biopharma Ltd., H2 2015
Gastroenteritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Gastroenteritis - Pipeline by UMN Pharma Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Gastroenteritis Therapeutics - Recent Pipeline Updates, H2 2015
List of Figures
Number of Products under Development for Gastroenteritis, H2 2015
Number of Products under Development for Gastroenteritis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report